My first trip to India was to participate in a workshop on health technology assessment (HTA) organized by the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) and the Health Intervention and Technology Assessment Program (HITAP) in Puducherry, India on 3-5 October 2019.

This policy brief provides a summary of a recent review of the definition of rare diseases, high cost and how HTA has been used in the case of rare diseases in seven countries. The countries were purposively selected based on them having established HTA policies and availability of resources in the

There is a growing demand for public health insurance programmes to reimburse high-cost medicines, including those that do not represent good value-for-money. This demand is likely to inhibit financial sustainability, given the growth of new technologies and public demands for expanded access to car

Achieving universal access to essential healthcare products remains a critical challenge across low- and middle-income countries (LMICs). While individual countries may have made notable strides in strengthening their procurement and regulatory systems, regional disparities in access, affordability,

This project evaluates Thailand’s maternal acellular pertussis vaccination policy after its inclusion in the Universal Health Coverage benefit package. Although the vaccine is available free of charge, uptake among pregnant women remained low in 2024. The study combines health economic modelling, budget impact analysis, and quantitative and quali